Heparin-induced Platelet Antibody (HIPA)

CPT: 86022
Print Share

Test Details


  • Heparin-associated Thrombocytopenia Antibody (HATA)
  • Heparin-induced Thrombocytopenia Antibody (HITA)


Assist in the diagnosis of heparin-induced thrombocytopenia


HIPA results should not be the sole basis for establishing the diagnosis of heparin-induced thrombocytopenia. Some patients with HIPA will not develop symptoms of heparin-induced thrombocytopenia (HIT). Microbial contamination, lipemia, icterus, or hemolysis may interfere with this test and immune complexes or immunoglobulin aggregates in the patient sample can produce false-positive results. Heparin in the sample (>1 unit/mL) can produce false-negative results.


HIPA is measured by enzyme immunoassay (EIA) using platelet factor 4 complexed polyvinyl sulfonate (PVS) that is coated to the wells of a microtiter plate. The PVS acts like heparin, exposing antigenic sites for HIPA binding.

Reference Interval

0.0−0.4 OD units

Additional Information

HIT, also referred to as heparin-associated thrombocytopenia (HAT), occurs in 1% to 5% of patients treated with standard unfractionated heparin.1-3 The most common form of HIT presents as a mild thrombocytopenia one to five days after initiation of heparin therapy. Type I HIT is not thought to be immune in etiology and may be mediated by a direct interaction between heparin and circulating platelets, causing platelet clumping or sequestration. This type of heparin-associated thrombocytopenia often occurs in patients on their first exposure to heparin.1 In this condition, platelet counts typically normalize within a few days, regardless of whether or not heparin therapy is continued.

Type II HIT is a much more clinically-significant, immune-mediated response to heparin that is frequently associated with the production of HIPA. Type II HIT can be associated with severe thrombosis, with the platelet count decreasing typically by 50%. The thrombocytopenia typically begins later than that of type I HIT, usually occurring some 5 to 10 days after the initiation of heparin therapy in patients who had never been previously exposed to heparin. Patients with prior exposure to heparin can develop thrombocytopenia more quickly on re-exposure due to earlier sensitization. In type II HIT, heparin is thought to bind to platelet factor 4, be found on platelets and endothelial cells, and to produce a conformational change, exposing antigenic sites for antibody formation.2 These antibodies bind to the heparin-PF4 complex and can activate platelets, resulting in the formation of microparticles and thrombin generation, with subsequent production of potentially severe venous or arterial thrombosis. Heparin treatment should be stopped and alternative anticoagulation considered in patients who develop type II HIT.1,2

Like other serologic (EIA based) assays, this assay has a high negative predictive value and only a moderate positive predictive value for HIT.4 Recent studies have shown that the magnitude (optical density, OD) of the result relative to the cutoff of 0.4 OD can provide useful information regarding the probability of developing HIT.4-8 The likelihood of developing HIT is significantly higher when the OD is >2.0 than when the OD is closer to the cutoff.4-8 One recent study revealed that patients with negative results just below the cutoff of 0.4 OD have a high probability of having positive results on repeat testing a few days later.9

Specimen Requirements


Serum, frozen


2 mL

Minimum Volume

1 mL


Red-top tube; do not use a gel-barrier tube.


Transfer serum to a plastic transport tube. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.

Storage Instructions


Causes for Rejection

Serum not separated from red cells; microbially contaminated, hemolyzed, lipemic, icteric, or heat-inactivated samples

Clinical Information


1. Adcock DM, Bethel MA, Macy PA. Coagulation Handbook. Aurora, Colo: Esoterix−Colorado Coagulation; 2006.
2. Warkentin TE. Heparin-induced thrombocytopenia. In Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, Pa: WB Saunders Co; 2002:355-372.
3. Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications−A review. Arch Pathol Lab Med. 2000 Nov; 124(11):1657-1566. 11079020
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep, 126(3 Suppl):311S-337S [published erratum: Chest. 2005 Jan; 127(1):416]. 15383477
5. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000 Sep 1; 96(5):1703-1708. 10961867
6. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003 Mar; 2(2):148-157 (review). 12901146
7. Fabris F, Luzzatto G, Soini B, et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med. 2002 Aug; 252(2):149-154. 12190890
8. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA.. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004 Dec, 2(12):2133-2137. 15613017
9. Refaai MA, Laposata M, Van Cott EM. Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia. Am J Clin Pathol. 2003 Jan; 119(1):61-65.12520698


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
150075 Heparin Induced Platelet 73818-7 150079 Heparin Induced Platelet Ab OD 73818-7

For Providers

Please login to order a test.


© 2018  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf